Pacific Biosciences of California stock
PACBNASDAQPacific Biosciences of California, Inc., HealthcareISIN US69404D1081
38Score 38 out of 100, Weak
Price and trend
82 / 100
Price history
+13% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 32% below its 52-week high. Largest decline in 16 years: 98% (February 2021 to May 2025).
Chart figures for advanced users
- SMA 50$1.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.60
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.11
- The lowest closing price of the last twelve months.
- Resistance$2.90
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Pacific Biosciences of California, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $612.34M, is number 73 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $160.01M (up 3.9% year on year) and a loss of $546.38M.
- For fiscal 2026, analysts expect on average revenue of $158.4M (down 1%) and adjusted earnings per share of −$0.46.
Show more
- MEQIRI Score 38 out of 100 (Weak): rank 582 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 82% since 2020.Capital allocation 18
- Loss-makingLoss of $131.23M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 94% a year over the last 12 months.Stability 26
Its standout strengths are technical analysis and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 39 to 38.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.4% on the twelve months before. Revenue has grown strongly since 2007, at around 27% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 32%, operating −348%, net −341%. Last 12 months: net −81%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 9 Feb 2027in 89 days
- Last reported
- 4 Nov 2026EPS reported −$0.11 (expected −$0.13)above expectations
Analyst estimates
- Earnings per share
- −$0.46+3.3%
- Revenue
- $158.4M−1.2%
- Earnings per share
- −$0.450.0%
- Revenue
- $179.72M−3.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −18.8%2026 revenue guidance lowered to $155 to $165 million, gross margin now only 35% to 37%, and cash flow breakeven pushed to 2028 from the end of 2027.
“Given the dynamics that Mark cited, we are lowering our revenue expectations for 2026 to $155 million to $165 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $2.09M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Pacific Biosciences of California
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 38
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- BioventusBVS $752.53M61
- Synektik Spólka AkcyjnaSNT.WA $709.44M77
- Senseonics HoldingsSENS $684.97M44
- Xvivo PerfusionXVIVO.ST $653.35M50
- Tactile Systems TechnologyTCMD $607.75M68
- Sight SciencesSGHT $606.92M48
- Anteris Technologies GlobalAVR $604.24M35
- MedistimMEDI.OL $599.88M80
ETFs that hold Pacific Biosciences of California
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 0.76% | 0.68% | €5.31M |
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.49% | 0.50% | €127.06M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.07% | 0.40% | €1.49B |
Show 3 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.05% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2016)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.